Close this search box.

Sensus Healthcare to Participate in 2017 South Beach Symposium on February 9 – 12 in Miami

February 7, 2017
— Joe Sardano, Sensus Healthcare CEO, to Participate in CEO Forum on February 11
— Sensus Healthcare Medical Advisory Board Members to Host SRT Workshops on February 9

BOCA RATON, Fla., Feb. 7, 2017Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the company will participate in the 2017 South Beach Symposium (SBS) at the Loews Miami Beach Hotel in Miami Beach, Fla., on February 912.

On February 11 at 4:30 p.m. ET, Joe Sardano, Sensus Healthcare CEO, will participate in the Annual South Beach Symposium Industry CEO Forum to discuss “The Future of Innovation in Dermatology and Aesthetics in an Era of Healthcare Upheaval.” Joe will join prominent leaders and colleagues from the industry, including Doug Abel, Sinclair U.S. CEO; Miles Harrison, Galderma Laboratories President and General Manager; Eduardo Sanchiz, Almirall CEO; Ann Smith, Ferndale Healthcare President and CEO, and Neal Walker, DO, Aclaris Therapeutics President and CEO.

“It is an honor to participate in the Annual South Beach Symposium Industry CEO Forum,” said Sardano. “Every year, we look forward to attending this prominent industry event to showcase our innovative SRT technology. It’s an exciting opportunity to represent Sensus among a collection of industry leaders and participate in the discussion on the future of innovation in dermatology and aesthetics. Our proprietary SRT technology for the treatment of non-melanoma skin cancers and keloids is already complementing the industry as it progresses into the future.”

Sensus Healthcare Medical Advisory Board Members will also host various SRT panel discussions throughout the day on February 9. Drs. Mark Nestor, MD, PhD and South Beach Symposium founder; David Goldberg, MD, JD; Clay Cockerell, MD; Brian Berman, MD, PhD, and William I. Roth, MD, will discuss a variety of SRT topics – ranging from a certification course for dermatology to an introduction / literature review on SRT for treating non-melanoma skin cancer specifically. In addition, an abstract that was co-authored by Dr. George Schmieder, DO, FAOCD, FAAD, will be presented as a poster at the SBS, on the topic of keloid SRT treatment. Schmieder uses the Sensus technology to treat patients at his practice in Orange Park, Fla.

“Given the high incidence of skin cancer which will affect one in five Americans patients are consulting their Dermatologists for new treatment options. SRT represents a highly effective, safe, non-invasive alternative to surgery,” said Dr. Mark Nestor, MD, PhD. “The Sensus Medical Advisory Board Members understand how this revolutionary SRT technology can benefit their patients. The educational sessions at the Symposium will highlight the benefits of SRT, as well as the importance of getting the word out to patients in need all over the world.”

The South Beach Symposium is an annual four-day event that gathers medical professionals to deliver educational content on the newest therapies, technologies, procedures and practice guidelines for physicians and practitioners in the dermatology and aesthetic medicine fields. SBS offers multiple educational tracks that allow medical professionals from both clinical and aesthetic dermatology practices to participate in focused education through the track of their choice.

For more information or to register, please visit the South Beach Symposium website.

About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

Public Relations:
Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
Phone: 212-896-1241 / 212-896-1206
Email: [email protected] / [email protected]

Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: [email protected] / [email protected]

To view the original version on PR Newswire, visit:–12-in-miami-300403110.html

SOURCE Sensus Healthcare